PACIRA BIOSCIENCES, INC. Revenue from Contract with Customer, Including Assessed Tax
PACIRA BIOSCIENCES, INC. (PCRX) reported Revenue from Contract with Customer, Including Assessed Tax of $117.48 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-30.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2020-10-30
- PACIRA BIOSCIENCES, INC. revenue from contract with customer, including assessed tax for the quarter ending 2020-09-30 was $117.48M, a 12.23% increase year-over-year.
- PACIRA BIOSCIENCES, INC. revenue from contract with customer, including assessed tax for the quarter ending 2020-06-30 was $75.50M, a 26.41% decline year-over-year.
- PACIRA BIOSCIENCES, INC. revenue from contract with customer, including assessed tax for the quarter ending 2020-03-31 was $105.68M, a 15.74% increase year-over-year.
- PACIRA BIOSCIENCES, INC. revenue from contract with customer, including assessed tax for the quarter ending 2019-09-30 was $104.69M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month |
|---|---|---|---|
| 2020-09-30 | $117.48M 10-Q · filed 2020-10-30 | $192.99M derived: sum of 2 quarters · filed 2020-10-30 | $298.67M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $75.50M 10-Q · filed 2020-08-06 | $181.19M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $105.68M 10-Q · filed 2020-05-07 | ||
| 2019-09-30 | $104.69M 10-Q · filed 2020-10-30 | $207.29M derived: sum of 2 quarters · filed 2020-10-30 | $298.60M 10-Q · filed 2020-10-30 |
| 2019-06-30 | $102.60M 10-Q · filed 2020-08-06 | $193.92M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $91.31M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |